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: Novel polymorphs of Lorlatinib and their processes for the prepar

Novel polymorphs of Lorlatinib and their processes for the preparation thereof
Field of the invention:
The present invention provides novel polymorphs of (10R)-7-amino-12-fluoro-2,10,
16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h]

[2,5,11]

benzoxa diazacyclotetradecine-3-carbonitrile represented by following structural formula-1
and their processes for the preparation thereof.

Formula-1
Background of the invention:
(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8methenopyrazolo[4,3h][2,5,11] benzoxadiazacyclotetradecine-3-carbonitrile is commonly
known as Lorlatinib, which was approved in US & Europe under the brand names of
Lorbrena and Lorviqua respectively for the treatment of anaplastic lymphoma kinase (ALK)positive metastatic non-small cell lung cancer.

Formula-1
Lorlatinib or pharmaceutically acceptable salts are described in US 8680111 B2.
US 9637500 B2 patent describes hydrated crystalline form 1, form 2 and acetic acid
solvate form 3 of Lorlatinib and their process for the preparation.
WO2017175091A1 PCT publication describes crystalline anhydrous form 1 and
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crystalline hydrate form 2 of Lorlatinib maleate and their processes for the preparation.
US 10420749 B2 patent describes anhydrous crystalline form-7 of Lorlatinib and its
process for the preparation.
WO2019073347 A1 PCT publication describes hydrated crystalline form 24 of
Lorlatinib and its process for the preparation.
WO2019209633A1 PCT publication describes crystalline form Z, form Ul, form U2,
form Gamma, form Epsilon, form X, form El and form E2 of Lorlatinib and its fumarate
form Fl, benzoate form Bl, nicotinate form Nl, mesylate form Sl, tosylate form Tl,
hydrobromide form Hl, L-malate form Ll, citrate form Cl, L-tartarate form Rl and maleate
forms Ml, M2, M4 and M5 and their process for the preparation.
There is a still develop further polymorphs of Lorlatinib to meet the
pharmaceuticals requirements.
Since the development of new polymorphic forms of an active pharmaceutical
ingredient provides new opportunity to improve the performance characteristics of
pharmaceutical finished product, the development of new polymorphic forms is always
encouraged.
Furthermore, solid state study of an active pharmaceutical ingredient aims to widen
the variety of crystalline forms that a formulation scientist has available for designing a
pharmaceutical dosage form with desired characteristics.
After numerous trials and earnest efforts, the present inventors found novel crystalline
polymorphs of Lorlatinib, which are useful and suitable for the preparation of various
pharmaceutical compositions.
Brief description of the invention:
The first embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-M.
The second embodiment of the present invention provides a process for the
preparation of crystalline form-M of Lorlatinib.
The third embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-S.
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The fourth embodiment of the present invention provides a process for the
preparation of crystalline form-S of Lorlatinib.
The fifth embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-N.
The sixth embodiment of the present invention provides a process for the preparation
of crystalline form-N of Lorlatinib.
The seventh embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-S1.
The eighth embodiment of the present invention provides a process for the
preparation of crystalline form-S1 of Lorlatinib.
The ninth embodiment of the present invention is to provide a process for the
preparation of amorphous form of Lorlatinib.
Brief description of the drawings:
Figure-1: Illustrates the powder X-Ray diffraction pattern of crystalline form-M of
Lorlatinib.
Figure-2: Illustrates the powder X-Ray diffraction pattern of crystalline form-S of Lorlatinib.
Figure-3: Illustrates the powder X-Ray diffraction pattern of crystalline form-N of
Lorlatinib.
Figure-4: Illustrates the powder X-Ray diffraction pattern of crystalline form-S1 of
Lorlatinib.
Figure-5: Illustrates the powder X-Ray diffraction pattern of amorphous form of Lorlatinib.
Figure-6: Illustrates the powder X-Ray diffraction pattern of crystalline form-M of
Lorlatinib obtained according to example-10.

Detailed description of the invention:
As used herein the term “suitable solvent” or solvent used in the present invention
refers to “hydrocarbon solvents” such as n-hexane, n-heptane, cyclohexane, pet ether,
benzene, toluene, pentane, cycloheptane, methyl cyclohexane, ethylbenzene, m-, o-, or pxylene, or naphthalene and the like; “ether solvents” such as dimethoxymethane,
tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl
3
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ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol
diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, 1,2-dimethoxy
ethane and the like; “ester solvents” such as methyl acetate, ethyl acetate, isopropyl acetate,
n-butyl acetate and the like; “polar-aprotic solvents such as dimethylacetamide (DMA),
dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP) and
the like; “chloro solvents” such as dichloromethane, dichloroethane, chloroform, carbon
tetrachloride and the like; “ketone solvents” such as acetone, methyl ethyl ketone, methyl
isobutylketone and the like; “nitrile solvents” such as acetonitrile, propionitrile,
isobutyronitrile and the like; “alcohol solvents” such as methanol, ethanol, n-propanol,
isopropanol, n-butanol, isobutanol, t-butanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2trifluoroethanol, ethylene glycol, 1,2-propanediol (propylene glycol), 2-methoxyethanol, l, 2ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol,
diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol and the
like; “polar solvents” such as water or mixtures thereof.
The first embodiment of the present invention provides a novel crystalline form of
Lorlatinib herein after designated as crystalline form-M.
In an aspect of first embodiment provides the crystalline form-M of Lorlatinib
characterized by its Powder X-Ray diffractogram substantially in accordance with figure-1.
The second embodiment of the present invention provides a process for the
preparation of crystalline form-M of Lorlatinib, comprising:
a) dissolving Lorlatinib in 2-butanol,
b) isolating crystalline form-M of Lorlatinib.
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to
reflux temperature of the solvent used; isolating crystalline form-M in step-b) is by solvent
removal by known techniques which are selected from filtration, cooling the mixture to lower
temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or
by combining with an anti-solvent.
In the above process, step a) or step-b) optionally involve seeding with crystalline
4
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form-M of Lorlatinib.
The third embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-S.
In an aspect of third embodiment provides the crystalline form-S of Lorlatinib
characterized by its powder X-Ray diffractogram as illustrated in figure-2.
The fourth embodiment of the present invention provides a process for the
preparation of crystalline form-S of Lorlatinib, comprising:
a) dissolving Lorlatinib in isopropanol,
b) isolating crystalline form-S of Lorlatinib.
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to
reflux temperature of the solvent used; isolating crystalline form-S in step-b) is by solvent
removal by known techniques which are selected from cooling the mixture to lower
temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or
by combining with an anti-solvent, wherein anti-solvent is selected from water.
In the above process, step a) or step-b) optionally involve seeding with crystalline
form-S of Lorlatinib.
The fifth embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-N.
In an aspect of fifth embodiment provides the crystalline form-N of Lorlatinib
characterized by its powder X-Ray diffractogram as illustrated in figure-3.
The sixth embodiment of the present invention provides a process for the preparation
of crystalline form-N of Lorlatinib, comprising:
a) dissolving Lorlatinib in ethanol,
b) isolating crystalline form-N of Lorlatinib.
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to
reflux temperature of the solvent used; isolating crystalline form-N in step-b) is by solvent
removal by known techniques which are selected from filtration, cooling the mixture to lower
5

Published by Technical Disclosure Commons, 2020

6

Defensive Publications Series, Art. 3912 [2020]

temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or
by combining with an anti-solvent, wherein anti-solvent is selected from hydrocarbon
solvents.
In the above process, step a) or step-b) optionally involve seeding with crystalline
form-N of Lorlatinib.
The seventh embodiment of the present invention provides a novel crystalline form of
Lorlatinib, herein after designated as crystalline form-S1.
In an aspect of seventh embodiment provides the crystalline form-S1 of Lorlatinib
characterized by its powder X-Ray diffractogram as illustrated in figure-4.
The eighth embodiment of the present invention provides a process for the
preparation of crystalline form-S1 of Lorlatinib, comprising:
a) dissolving Lorlatinib in n-pentanol,
b) isolating crystalline form-S1 of Lorlatinib.
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to
reflux temperature of the solvent used; isolating crystalline form-S1 in step-b) is by solvent
removal by known techniques which are selected from filtration, cooling the mixture to lower
temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or
by combining with an anti-solvent, wherein anti-solvent is selected from hydrocarbon
solvents.
In the above process, step a) or step-b) optionally involve seeding with crystalline
form-S1 of Lorlatinib.
The ninth embodiment of the present invention provided a process for the preparation
of amorphous form of Lorlatinib comprises:
a) dissolving Lorlatinib to a solvent,
b) isolating the amorphous form of Lorlatinib.
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to
reflux temperature of the solvent used; solvent is selected from ketone solvents, ester
solvents or mixtures thereof and the like; isolating amorphous form in step-b) is by solvent
6
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removal by known techniques which are selected from distillation, filtration, cooling the
mixture to lower temperatures to precipitate the solid followed by filtration of the mixture; or
by combining with an anti-solvent selected from hydrocarbon solvents, water or mixtures
thereof and the like.
In an aspect of the ninth embodiment provides amorphous form of Lorlatinib
characterized by its powder X-Ray difractogram substantially in accordance with figure-5.
The crystalline form-M, form-S, form-N, form-S1 and amorphous form of Lorlatinib
of the present invention are prepared by the processes as illustrated in the present invention
and they are useful for the preparation of various pharmaceutical compositions formulated in
a manner suitable for the route of administration to be used where at least a portion of
Lorlatinib is present in the composition in particular polymorphic form mentioned.
An embodiment of the present invention provides the use of crystalline form-M,
form-S, form-N, form-S1 and amorphous form of Lorlatinib for the preparation of
pharmaceutical formulations.
The other embodiment of the present invention provides pharmaceutical composition
comprising crystalline form-M or form-N or form-S or form-S1 or amorphous of Lorlatinib
or mixture thereof and at least one pharmaceutically acceptable excipient. As used herein, the
term "pharmaceutical compositions" or "pharmaceutical formulations" include tablets, pills,
powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection
preparations.
In an aspect of the present invention provides a pharmaceutical composition
comprising crystalline forms or amorphous prepared according to the present invention and
one or more pharmaceutically acceptable carriers for the treatment of anaplastic lymphoma
kinase (ALK)-positive metastatic non-small cell lung cancer.
Crystalline forms or amorphous form of Lorlatinib obtained according to the present
invention is having a purity of >98%, preferably >99%, more preferably >99.5% by HPLC.
Crystalline forms or amorphous form of Lorlatinib produced by the processes of the
present invention can be further micronized or milled to get desired particle size to achieve
7
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desired solubility profile based on different forms of pharmaceutical composition
requirements. Techniques that may be used for particle size reduction include but not limited
to single or multi-stage micronization using cutting mills, pin/cage mills, hammer mills, jet
mills, fluidized bed jet mills, ball mills and roller mills. Milling or micronization may be
performed before drying or after drying of the product.
Crystalline forms or amorphous form of Lorlatinib obtained according to the present
invention has particle size of less than about 250 μm or less than about 200 μm or less than
about 150 μm or less than about 100 μm or less than about 50 μm or any other suitable
particle sizes.
Lorlatinib used as an input for the preparation of crystalline forms or amorphous form
of Lorlatinib obtained according to the present invention is prepared by any of the processes
disclosed in literature such as US 8680111 B2 or other references.
PXRD (Powder X-Ray diffractogram) Method of Analysis:
The PXRD analysis of compounds of the present invention was carried out by using
BRUKER-Axis/D8 ADVANCE (DAVINCI) X-Ray diffractometer using CuKα radiation of
wavelength 1.5406A° and at a continuous scan speed of 0.03°/min.

The best mode of carrying out the present invention is illustrated by the below
mentioned examples. These examples are provided as illustration only and hence should not
be considered as limitation of the scope of the invention.
Examples:
Example-1: Preparation of crystalline form-M of Lorlatinib
Dissolved Lorlatinib (500 mg) in 2-butanol (5 ml) at 95-100°C and stirred for 10 minutes at
the same temperature. Cooled the solution to 0-5°C and stirred for 15 minutes at the same
temperature. Filtered the precipitated solid and dried to get the title compound.
Yield: 400 mg. PXRD of the obtained compound is as illustrated in figure-1.
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Example-2: Preparation of crystalline form-S of Lorlatinib
Dissolved Lorlatinib (1 g) in isopropanol (4 ml) at 80-85°C and stirred for 10 minutes at the
same temperature. Water (200 µl) was added to resultant solution, cooled the mixture to 05°C and stirred for 80 minutes at the same temperature. Filtered the precipitated solid and
dried to get the title compound.
Yield: 800 mg. PXRD of the obtained compound is as illustrated in figure-2.
Example-3: Preparation of crystalline form-S of Lorlatinib
Dissolved Lorlatinib (2 g) in isopropanol (10 ml) at 80-85°C and stirred for 10 minutes at the
same temperature. Cooled the resultant solution to 25-30°C and stirred for 30 minutes at the
same temperature. Filtered the precipitated solid and dried to get the title compound.
Yield: 1.8 g. PXRD of the obtained compound is similar to figure-2.
Example-4: Preparation of crystalline form-N of Lorlatinib
Dissolved Lorlatinib (2 g) in ethanol (20 ml) at 25-30°C. The resultant solution was added to
pre-cooled n-heptane (300 ml) at 0-5°C and stirred for 30 minutes at the same temperature.
Filtered the precipitated solid and dried to get the title compound.
Yield: 1500 mg. PXRD of the obtained compound is as illustrated in figure-3.
Example-5: Preparation of crystalline form-S1 of Lorlatinib
Dissolved Lorlatinib (2 g) in n-pentanol (100 ml) at 80-85°C. The resultant solution was
added to pre-cooled n-heptane (300 ml) at 0-5°C and stirred for 20 minutes at the same
temperature. Filtered the precipitated solid and dried to get the title compound.
Yield: 1 g. PXRD of the obtained compound is as illustrated in figure-4.
Example-6: Preparation of Amorphous form of Lorlatinib
Dissolved Lorlatinib (500 mg) in 2-pentanone (1 ml) at 25-30°C. The resultant solution was
cooled to 0-5°C. n-Heptane (30 ml) was added to the above solution at 0-5°C and stirred for
90 minutes at the same temperature. Filtered the precipitated solid and dried to get the title
compound.
Yield: 460 mg. PXRD of the obtained compound is as illustrated in figure-5.
Example-7: Preparation of Amorphous form of Lorlatinib
Dissolved Lorlatinib (500 mg) in acetone (3 ml) at 25-30°C. The resultant solution was
added to pre-cooled mixture of n-heptane and water (60 ml) at 0-5°C and stirred for 90
9
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minutes at the same temperature. Filtered the precipitated solid and dried to get the title
compound.
Yield: 450 mg.
Example-8: Preparation of Amorphous form of Lorlatinib
Dissolved Lorlatinib (200 mg) in ethyl acetate (3 ml) at 70-75°C. The resultant solution was
cooled to 0-5°C. n-Heptane (30 ml) was added to above solution at 0-5°C and stirred for 10
minutes at the same temperature. Filtered the precipitated solid and dried to get the title
compound.
Yield: 150 mg.
Example-9: Preparation of Amorphous form of Lorlatinib
Dissolved Lorlatinib (200 mg) in methyl isobutyl ketone (3 ml) at 95-100°C. The resultant
solution was cooled to 0-5°C. n-Heptane (30 ml) was added to above solution at 0-5°C and
stirred for 10 minutes at the same temperature. Filtered the precipitated solid and dried to get
the title compound.
Yield: 150 mg.
Example-10: Preparation of crystalline form-M of Lorlatinib
Dissolved Lorlatinib (15 g) in 2-butanol (150 ml) at 95-100°C. Cooled the solution to 0-5°C
and stirred for 1 hour at the same temperature. Filtered the precipitated solid and dried to get
the title compound.
Yield: 12 g. PXRD of the obtained compound is as illustrated in figure-6.
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Drawings

Figure-1

Figure-2
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Figure-3

Figure-4
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Figure-5

Figure-6

*******
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